Literature DB >> 20855458

Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity.

Fang Li1, Brooke L Fridley, Alice Matimba, Krishna R Kalari, Linda Pelleymounter, Irene Moon, Yuan Ji, Gregory D Jenkins, Anthony Batzler, Liewei Wang, Richard M Weinshilboum.   

Abstract

Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood. To test the hypothesis that variation in the expression of genes within the "thiopurine pathway" might influence 6-MP and 6-TG sensitivity, we generated basal gene expression profiles and IC(50) values for both of these thiopurine drugs using a model system consisting of 194 Human Variation Panel lymphoblastoid cell lines. Association analysis showed that thiopurine S-methyltransferase, ecto-5'-nucleotidase (NT5E), and multidrug resistance protein 4 (ABCC4) expression were correlated with thiopurine cytotoxicity. Those observations suggested the possible existence of a "thiopurine cellular circulation" involving nucleotide efflux by ABCC4, hydrolysis of thiopurine nucleotide monophosphates outside of the cell by NT5E, and subsequent transport of thiopurine nucleosides back into the cell by nucleoside transporters. The existence of this cellular circulation was confirmed by a series of functional experiments performed with cultured cells stably or transiently transfected with ABCC4 and/or NT5E. Because of the central role of NT5E in this cellular circulation, the NT5E gene was resequenced using 287 DNA samples from three ethnic groups, with the identification of 68 single nucleotide polymorphisms (SNPs), 46 of which were novel. Several SNPs in the 5'-flanking region of NT5E were highly correlated with expression, rs9450278 having the lowest p value (p = 2.4 × 10(-10), R = -0.376). The thiopurine cellular circulation and genetic polymorphisms for genes encoding the proteins involved should be incorporated into future studies of thiopurine drug therapy and effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855458      PMCID: PMC2993460          DOI: 10.1124/dmd.110.035220

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  38 in total

1.  Purification and properties of 5-phosphoribosyl pyrophosphate amidotransferase from adenocarcinoma 755 cells.

Authors:  D L Hill; L L Bennett
Journal:  Biochemistry       Date:  1969-01       Impact factor: 3.162

2.  Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides.

Authors:  B S Tay; R M Lilley; A W Murray; M R Atkinson
Journal:  Biochem Pharmacol       Date:  1969-04       Impact factor: 5.858

3.  Are children with lymphoblastic leukaemia resistant to 6-mercaptopurine because of 5'-nucleotidase?

Authors:  R Pieters; D R Huismans; A J Veerman
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

Review 4.  The equilibrative nucleoside transporter family, SLC29.

Authors:  Stephen A Baldwin; Paul R Beal; Sylvia Y M Yao; Anne E King; Carol E Cass; James D Young
Journal:  Pflugers Arch       Date:  2003-06-28       Impact factor: 3.657

5.  A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy.

Authors:  G R Erdmann; L A France; B C Bostrom; D M Canafax
Journal:  Biomed Chromatogr       Date:  1990-03       Impact factor: 1.902

6.  Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

Authors:  L Lennard; C A Rees; J S Lilleyman; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

7.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

8.  Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.

Authors:  L Lennard; J A Van Loon; J S Lilleyman; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

9.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

10.  Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells.

Authors:  L Lennard
Journal:  J Chromatogr       Date:  1987-12-25
View more
  6 in total

1.  Gene set analysis of purine and pyrimidine antimetabolites cancer therapies.

Authors:  Brooke L Fridley; Anthony Batzler; Liang Li; Fang Li; Alice Matimba; Gregory D Jenkins; Yuan Ji; Liewei Wang; Richard M Weinshilboum
Journal:  Pharmacogenet Genomics       Date:  2011-11       Impact factor: 2.089

2.  Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.

Authors:  Alice Matimba; Fang Li; Alina Livshits; Cher S Cartwright; Stephen Scully; Brooke L Fridley; Gregory Jenkins; Anthony Batzler; Liewei Wang; Richard Weinshilboum; Lynne Lennard
Journal:  Pharmacogenomics       Date:  2014-03       Impact factor: 2.533

3.  Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?

Authors:  Sofie Haglund; Sven Almer; Curt Peterson; Jan Söderman
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

4.  Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  E Mohanan; J C Panetta; K M Lakshmi; E S Edison; A Korula; N A Fouzia; A Abraham; A Viswabandya; V Mathews; B George; A Srivastava; P Balasubramanian
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

5.  Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.

Authors:  Brooke L Fridley; Taraswi M Ghosh; Alice Wang; Rama Raghavan; Junqiang Dai; Ellen L Goode; Jatinder K Lamba
Journal:  Front Genet       Date:  2016-03-22       Impact factor: 4.599

Review 6.  Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring.

Authors:  Sheng Zhang Lim; Eng Wee Chua
Journal:  Front Pharmacol       Date:  2018-10-08       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.